Products Suvorexant was approved in the United States in 2014 as the first agent in the orexin receptor antagonist group in the form of film-coated tablets (Belsomra). Structure and properties Suvorexant (C23H23ClN6O2, Mr = 450.9 g/mol) exists as a white powder that is insoluble in water. It is a benzoxazole, diazepane and triazole derivative. Effects … Suvorexant
Products Orexin receptor antagonists are commercially available in tablet form. The first agent in this group to be approved in the United States was suvorexant (Belsomra) in 2014. Lemborexant (Dayvigo) followed in 2019. Structure and properties Orexin receptor antagonists are characterized by a central ring structure to which heterocycles are attached on both sides. Effects … Orexin Receptor Antagonists
Products Almorexant is not commercially available. Clinical development was discontinued by Actelion and GlaxoSmithKline (GSK) in 2011 due to adverse effects. Structure and properties Almorexant (C29H31F3N2O3, Mr = 512.6 g/mol) is a tetrahydroisoquinoline derivative. It is structurally related to the opioid methopholine. Effects Almorexant has sleep-inducing properties. It is a selective and dual antagonist at … Almorexant
